- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: R17934, Oncodazole, NSC238159 中文名稱:諾考達唑
Nocodazole是一種微管聚合的快速可逆抑制劑,也抑制Abl、Abl(E255K)和Abl(T315I),對應的IC50值分別為0.21 μM,0.53 μM和0.64 μM。Nocodazole可提高CRISPR介導的同源重組效率,對增強精確的基因編輯效力具有加成作用。Nocodazole可誘導凋亡。
Nocodazole Chemical Structure
CAS: 31430-18-9
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HepG2 | Function assay | 0.1 to 10 uM | 1 hr | Inhibition of TNFalpha-induced NFkappaB (unknown origin)-dependent transcriptional activity expressed in human HepG2 cells at 0.1 to 10 uM incubated for 1 hr prior to TNFalpha induction measured after 6 hrs by dual-luciferase reporter gene assay | 25827522 |
L1210 | Function assay | 0.3 uM | 24 hrs | Fraction of cell population of cultured lymphoid leukemia L1210 cells in mitosis at a dose of 0.3 uM after 24 hr, Mitotic index = 0.19 μM. | 7131483 |
NIH3T3 | Apoptosis assay | 0.5 ug/ml | 24 hrs | Induction of apoptosis in mouse NIH3T3 cells assessed as accumulation at subG1 phase at 0.5 ug/ml after 24 hrs by flow cytometry | 18247573 |
PC3M | Apoptosis assay | 0.5 ug/ml | 24 hrs | Induction of apoptosis in human PC3M cells assessed as accumulation at subG1 phase at 0.5 ug/ml after 24 hrs by flow cytometry | 18247573 |
NRK | Function assay | 30 uM | 60 mins | Golgi-disturbing activity in golgi apparatus of rat NRK cells assessed as microtubule depolymerization-associated golgi fragmentation at 30 uM after 60 mins by Hoechst 3342 staining-based immunofluorescence microscopy | 20189813 |
Vero | Function assay | 5 ug/ml | 30 mins | Effect on disruption of microtubules in african green monkey Vero cells at 5 ug/ml after 30 mins by immunofluorescence method | 19182783 |
MCF7 | Apoptosis assay | 2.5 uM | 48 hrs | Induction of apoptosis in human MCF7 cells assessed as nuclear fragmentation at 2.5 uM after 48 hrs by DAPI staining | 21194809 |
MCF7 | Function assay | 2.5 uM | 48 hrs | Inhibition of tubulin polymerization in human MCF7 cells assessed as disrupted microtubule organization at 2.5 uM after 48 hrs by microscopic analysis | 21194809 |
A549 | Apoptosis assay | 10 to 100 nM | 48 hrs | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 10 to 100 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis | 21916509 |
A549 | Apoptosis assay | 10 to 100 nM | 48 hrs | Induction of apoptosis in human A549 cells assessed as necrotic cells at 10 to 100 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis | 21916509 |
A549 | Cell cycle assay | 1 uM | 48 hrs | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis relative to control | 22361684 |
SKBR3 | Function assay | 50 to 100 nM | 24 hrs | Induction of Hsp27 phosphorylation in human SKBR3 cells at 50 to 100 nM after 24 hrs by SDS-PAGE analysis | 22435708 |
SKBR3 | Function assay | 0.2 to 1 uM | 24 hrs | Induction of Hsp27 phosphorylation in human SKBR3 cells at 0.2 to 1 uM after 24 hrs by SDS-PAGE analysis | 22435708 |
MCF7 | Function assay | 4 uM | 24 hrs | Inhibition of microtubule organization in human MCF7 cells at 4 uM after 24 hrs by immunofluorescence analysis | 22982122 |
HeLa | Function assay | 1 uM | 24 hrs | Inhibition of tubulin polymerization in human HeLa cells assessed as tubulin soluble fraction at 1 uM after 24 hrs by immunohistochemistry analysis | 23313639 |
HeLa | Function assay | 1 uM | 24 hrs | Mitotic arrest in human HeLa cells assessed as increase in accumulation at G2/M phase at 1 uM for 24 hrs by PI staining/FACS analysis | 24530033 |
HeLa | Cell cycle assay | 2 uM | 24 hrs | Cell cycle arrest at G2/M phase in human HeLa cells assessed as increase in cyclin B1 expression at 2 uM after 24 hrs by immunoblot analysis relative to control | 25499929 |
HeLa | Cell cycle assay | 2 uM | 24 hrs | Cell cycle arrest at G2/M phase in human HeLa cells assessed as soluble form of tubulin at 2 uM after 24 hrs by immunoblot analysis relative to control | 25499929 |
DU145 | Function assay | 50 uM | 48 hrs | Disruption of microtubule network in human DU145 cells at 50 uM after 48 hrs by immunohistochemistry analysis | 25615796 |
HeLa | Function assay | 25 uM | 24 hrs | Effect on PCM1 protein in human HeLa cells assessed as accumulation of pericentriolar material at 25 uM after 24 hrs by immunofluorescence microscopy | 25050880 |
MCF7 | Function assay | 1 uM | 4 hrs | Induction of tubulin depolymerization in human MCF7 cells at 1 uM after 4 hrs by sedimentation assay and Western blotting method | 25369367 |
DU145 | Function assay | 1.5 uM | 48 hrs | Reduction in mitochondrial membrane potential in human DU145 cells at 1.5 uM incubated for 48 hrs by JC1 dye staining based flow cytometry | 26330077 |
SKBR3 | Function assay | 2.5 uM | 24 hrs | Induction of microtubule destabilization in human SKBR3 cells assessed as soluble fraction of protein at 2.5 uM after 24 hrs by Western blot analysis | 26599530 |
HeLa | Function assay | 100 nM | 4 hrs | Inhibition of tubulin polymerization in human HeLa cells assessed as microtubule disruption in mitotic phase at 100 nM after 4 hrs by indirect immunofluorescence analysis | 26641132 |
HeLa | Function assay | 100 nM | 4 hrs | Inhibition of tubulin polymerization in human HeLa cells assessed as microtubule disruption in interphase at 100 nM after 4 hrs by indirect immunofluorescence analysis | 26641132 |
HeLa | Function assay | 0.1 uM | 24 hrs | Inhibition of tubulin polymerization in human HeLa cells assessed as shift of tubulin protein to soluble fraction at 0.1 uM after 24 hrs by Western blot analysis | 29501940 |
PC3MLN4 | Function assay | 1 uM | 24 hrs | Upregulation of Cyclin-B1 protein expression in human PC3MLN4 cells at 1 uM after 24 hrs by Western blot method | 29288939 |
PC3MLN4 | Function assay | 1 uM | 48 hrs | Disruption of microtubule dynamics in human PC3MLN4 cells at 1 uM after 48 hrs by immunofluorescence microscopic method | 29288939 |
MCF7 | Function assay | 1 uM | 4 hrs | Induction of tubulin depolymerization in human MCF7 cells at 1 uM after 4 hrs by Western blot method | 27689728 |
Jurkat | Function assay | 1 uM | 4 hrs | Induction of tubulin depolymerization in human Jurkat cells at 1 uM after 4 hrs by Western blot method | 27689728 |
MDA-MB-231 | Anticancer assay | 48 hrs | Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 0.042 μM. | 27130357 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay, IC50 = 0.04 μM. | 21705223 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay, IC50 = 0.04 μM. | 20537765 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against LT12 cells by XTT assay after 48 hrs, IC50 = 0.04 μM. | 17181164 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay, IC50 = 0.04 μM. | 19220018 | |
NCI60 | Growth inhibition assay | 48 hrs | Growth inhibition of human NCI60 cells incubated for 48 hrs by sulforhodamine B assay, GI50 = 0.0389 μM. | 27956038 | |
A549 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human A549 cells after 24 hrs by MTT assay, IC50 = 0.0366 μM. | 20110137 | |
PANC1 | Anticancer assay | 48 hrs | Anticancer activity against human PANC1 cells after 48 hrs by SRB assay, GI50 = 0.029 μM. | 27130357 | |
L1210 | Function assay | 48 hrs | Inhibitory concentration against proliferation of cultured lymphoid leukemia L1210 cells during 48 hrs, ID50 = 0.027 μM. | 7131483 | |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by SRB assay, GI50 = 0.02 μM. | 25827522 | |
MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 0.017 μM. | 25827522 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay, GI50 = 0.015 μM. | 25827522 | |
MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB cell proliferation assay, GI50 = 0.01 μM. | 29089233 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by SRB cell proliferation assay, GI50 = 0.01 μM. | 29089233 | |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by SRB cell proliferation assay, GI50 = 0.01 μM. | 29089233 | |
MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 0.01 μM. | 27688193 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay, GI50 = 0.01 μM. | 27688193 | |
PANC1 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay, GI50 = 0.01 μM. | 27688193 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay, IC50 = 0.006 μM. | 19220018 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against L1210 cells by XTT assay after 48 hrs, IC50 = 0.05 μM. | 17181164 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay, IC50 = 0.05 μM. | 17973361 | |
L12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat multidrug-resistant L12 cells after 48 hrs by XTT assay, IC50 = 0.05 μM. | 17973361 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay, IC50 = 0.05 μM. | 20537765 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay, IC50 = 0.05 μM. | 21705223 | |
U2OS | Function assay | 72 hrs | Induction of mitotic arrest in human U2OS cells assessed as mitotic index after 72 hrs by microscopic analysis, EC50 = 0.05 μM. | 24900887 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay, IC50 = 0.06 μM. | 17973361 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay, IC50 = 0.06 μM. | 19220018 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay, IC50 = 0.06 μM. | 21705223 | |
HeLa | Anticancer assay | 48 hrs | Anticancer activity against human HeLa cells after 48 hrs by SRB assay, GI50 = 0.063 μM. | 27130357 | |
MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.065 μM. | 28117204 | |
NCI-H460 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay, IC50 = 0.068 μM. | 21563750 | |
BT549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay, IC50 = 0.069 μM. | 21563750 | |
LT12 MDR | Antiproliferative assay | 48 hrs | Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs, IC50 = 0.07 μM. | 17181164 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay, IC50 = 0.07 μM. | 17973361 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay, IC50 = 0.07 μM. | 17973361 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay, IC50 = 0.07 μM. | 20537765 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay, IC50 = 0.07 μM. | 21705223 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay, IC50 = 0.07 μM. | 21705223 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay, IC50 = 0.07 μM. | 21705223 | |
451LU | Antiproliferative assay | 48 hrs | Antiproliferative activity against human 451LU cells after 48 hrs by alamar blue assay, IC50 = 0.072 μM. | 21563750 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against P388 cells by XTT assay after 48 hrs, IC50 = 0.08 μM. | 17181164 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay, IC50 = 0.08 μM. | 20537765 | |
SKOV3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay, IC50 = 0.08 μM. | 21563750 | |
SGC7901 | Growth inhibition assay | 72 hrs | Growth inhibition of human SGC7901 cells after 72 hrs by MTT assay, IC50 = 0.08 μM. | 25262051 | |
A549 | Anticancer assay | 48 hrs | Anticancer activity against human A549 cells after 48 hrs by SRB assay, GI50 = 0.08 μM. | 27130357 | |
SKBR3 | Growth inhibition assay | 48 hrs | Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay, IC50 = 0.084 μM. | 22850214 | |
HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.086 μM. | 28117204 | |
COLO205 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay, IC50 = 0.088 μM. | 21563750 | |
L1210 VCR | Antiproliferative assay | 48 hrs | Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs, IC50 = 0.09 μM. | 17181164 | |
L1210 | Antiproliferative assay | 48 hrs | Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay, IC50 = 0.09 μM. | 20537765 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.09 μM. | 28117204 | |
KB/HeLa | Cell cycle assay | 24 hrs | Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis, EC50 = 0.091 μM. | 17973361 | |
KB/HeLa | Cell cycle assay | 24 hrs | Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis, EC50 = 0.091 μM. | 19220018 | |
KB/HeLa | Cell cycle assay | 24 hrs | Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis, EC50 = 0.091 μM. | 20537765 | |
KB/HeLa | Cell cycle assay | 24 hrs | Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry, EC50 = 0.091 μM. | 21705223 | |
MiaPaCa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MiaPaCa cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.091 μM. | 28117204 | |
A549 | Cell cycle assay | 24 hrs | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by flow cytometry, EC50 = 0.1065 μM. | 20110137 | |
RKO | Antiproliferative assay | 48 hrs | Antiproliferative activity against RKO cells by XTT assay after 48 hrs, IC50 = 0.11 μM. | 17181164 | |
RKO | Cytotoxicity assay | 48 hrs | Cytotoxicity against human RKO cells after 48 hrs by XTT assay, IC50 = 0.11 μM. | 17973361 | |
RKO | Antiproliferative assay | 48 hrs | Antiproliferative activity against human RKO cells after 48 hrs by XTT assay, IC50 = 0.11 μM. | 20537765 | |
RKOp27 | Cytotoxicity assay | 48 hrs | Cytotoxicity against non induced human RKOp27 cells after 48 hrs by XTT assay, IC50 = 0.11 μM. | 21705223 | |
SW480 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay, IC50 = 0.12 μM. | 21563750 | |
A549 | Growth inhibition assay | 72 hrs | Growth inhibition of human A549 cells after 72 hrs by MTT assay, IC50 = 0.12 μM. | 25262051 | |
KB/HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs, IC50 = 0.14 μM. | 17181164 | |
KB/HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay, IC50 = 0.14 μM. | 17973361 | |
KB/HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay, IC50 = 0.14 μM. | 20537765 | |
KB/HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay, IC50 = 0.14 μM. | 21705223 | |
HT1080 | Growth inhibition assay | 72 hrs | Growth inhibition of human HT1080 cells after 72 hrs by MTT assay, IC50 = 0.14 μM. | 25262051 | |
NCI-H460 | Antiproliferative assay | 48 hrs | Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs, IC50 = 0.15 μM. | 17181164 | |
NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay, IC50 = 0.15 μM. | 17973361 | |
NCI-H460 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay, IC50 = 0.15 μM. | 20537765 | |
NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay, IC50 = 0.15 μM. | 21705223 | |
SKOV3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs, IC50 = 0.17 μM. | 17181164 | |
P388 ADR | Antiproliferative assay | 48 hrs | Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs, IC50 = 0.17 μM. | 17181164 | |
SKOV3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay, IC50 = 0.17 μM. | 17973361 | |
SKOV3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay, IC50 = 0.17 μM. | 20537765 | |
P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay, IC50 = 0.17 μM. | 20537765 | |
SKOV3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay, IC50 = 0.17 μM. | 21705223 | |
HeLa | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human HeLa cells after 24 to 48 hrs by trypan blue assay, IC50 = 0.178 μM. | 23445405 | |
DLD1 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay, IC50 = 0.19 μM. | 21563750 | |
SF268 | Antiproliferative assay | 48 hrs | Antiproliferative activity against SF268 cells by XTT assay after 48 hrs, IC50 = 0.3 μM. | 17181164 | |
SF268 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SF268 cells after 48 hrs by XTT assay, IC50 = 0.3 μM. | 17973361 | |
L12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat L12 cells after 48 hrs by XTT assay, IC50 = 0.3 μM. | 17973361 | |
SF268 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay, IC50 = 0.3 μM. | 20537765 | |
SF268 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SF268 cells after 48 hrs by XTT assay, IC50 = 0.3 μM. | 21705223 | |
LT12 | Antiproliferative assay | 48 hrs | Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay, IC50 = 0.4 μM. | 19220018 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells after 48 hrs by SRB assay, GI50 = 0.5 μM. | 20529689 | |
SK-N-SH | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay, GI50 = 0.65 μM. | 20529689 | |
HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.71 μM. | 23748152 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.81 μM. | 25131956 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay, GI50 = 0.81 μM. | 27344493 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.89 μM. | 25599948 | |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by SRB assay, IC50 = 0.9 μM. | 28988624 | |
MDA-MB-453 | Cytotoxicity assay | 48 hrs | Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay, IC50 = 0.91 μM. | 28923381 | |
MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.94 μM. | 25131956 | |
MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 0.94 μM. | 27344493 | |
MIAPaCa2 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay, GI50 = 0.95 μM. | 25131956 | |
MIAPaCa2 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by SRB assay, GI50 = 0.95 μM. | 27344493 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells after 48 hrs by SRB assay, LC50 = 1 μM. | 20529689 | |
HCT116 | Cytotoxicity assay | 48 hrs | Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay, IC50 = 1.06 μM. | 28923381 | |
HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 1.1 μM. | 25599948 | |
DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay, IC50 = 1.14 μM. | 28923381 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay, IC50 = 1.2 μM. | 28988624 | |
MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay, IC50 = 1.25 μM. | 28988624 | |
HCT116 | Anticancer assay | 48 hrs | Anticancer activity against human HCT116 cells after 48 hrs by MTT assay, IC50 = 1.262 μM. | 28789894 | |
IMR32 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay, IC50 = 1.3 μM. | 28988624 | |
A549 | Anticancer assay | 48 hrs | Anticancer activity against human A549 cells after 48 hrs by MTT assay, IC50 = 1.513 μM. | 28789894 | |
MCF7 | Anticancer assay | 48 hrs | Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay, IC50 = 1.6 μM. | 26231080 | |
DU145 | Anticancer assay | 48 hrs | Anticancer activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 1.698 μM. | 28789894 | |
MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 1.7 μM. | 25599948 | |
PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay, IC50 = 1.84 μM. | 28923381 | |
MDA-MB-231 | Anticancer assay | 48 hrs | Anticancer activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.862 μM. | 28789894 | |
A549 | Anticancer assay | 48 hrs | Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay, IC50 = 1.87 μM. | 26231080 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50 = 1.87 μM. | 28668476 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells after 48 hrs by MTT assay, IC50 = 2.31 μM. | 23748152 | |
SK-N-SH | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay, LC50 = 2.8 μM. | 20529689 | |
DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells after 48 hrs by MTT assay, IC50 = 2.8 μM. | 23748152 | |
HeLa | Anticancer assay | 48 hrs | Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay, IC50 = 2.83 μM. | 26231080 | |
HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50 = 2.83 μM. | 28668476 | |
DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 3.2 μM. | 25599948 | |
HaCaT | Cytotoxicity assay | 48 hrs | Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay, IC50 = 8.9 μM. | 26231080 | |
A549 | Cell cycle assay | 24 hrs | Cell cycle arrest in human A549 cells assessed as accumulation of cells in G2 phase after 24 hrs measured using propidium iodide staining by FACS analysis | 21863853 | |
Jurkat T | Function assay | 36 hrs | Induction of microtubule damage in human Jurkat T cells overexpressing Bcl2 after 36 hrs by immunostaining method | 22197393 | |
Jurkat T | Function assay | 36 hrs | Induction of microtubule damage in human Jurkat T cells overexpressing Neo after 36 hrs by immunostaining method | 22197393 | |
Jurkat T | Apoptosis assay | 36 hrs | Induction of apoptosis in human Jurkat T cells overexpressing Bcl2 assessed as cellular protrusions after 36 hrs by light microscopy | 22197393 | |
Jurkat T | Apoptosis assay | 36 hrs | Induction of apoptosis in human Jurkat T cells overexpressing Neo after 36 hrs by flow cytometry | 22197393 | |
Jurkat T | Apoptosis assay | 36 hrs | Induction of apoptosis in human Jurkat T cells overexpressing Neo assessed as cellular protrusions after 36 hrs by light microscopy | 22197393 | |
SGC7901 | Function assay | 48 hrs | Induction of distortions in tubulin assembly in human SGC7901 cells assessed as abnormal mitotic spindle formation at 2 fold IC50 level incubated for 48 hrs by immunofluorescence staining based fluorescence microscopy | 25262051 | |
HT1080 | Function assay | 48 hrs | Induction of distortions in tubulin assembly in human HT1080 cells assessed as abnormal mitotic spindle formation at 2 fold IC50 level incubated for 48 hrs by immunofluorescence staining based fluorescence microscopy | 25262051 | |
HeLa | Function assay | 24 hrs | Inhibition of tubulin polymerization in human HeLa cells assessed as increase in soluble tubulin fraction after 24 hrs by Western blot analysis | 28818768 | |
L1210 murine leukemia cell | Growth inhibition assay | In vitro for its inhibitory activity against L1210 murine leukemia cell growth, IC50=38 nM | 1738146 | ||
K562 | Function assay | Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase, EC50 = 0.082 μM. | 12852768 | ||
A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells by MTT assay, IC50 = 0.087 μM. | 21954851 | ||
KB/HeLa | Cell cycle assay | Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase, EC50 = 0.091 μM. | 17181164 | ||
MCF7 | Growth inhibition assay | Growth inhibition of human MCF7 cells by Sulforhodamine B assay, GI50 = 0.1 μM. | 21106458 | ||
MCF7 | Growth inhibition assay | Growth inhibition of human MCF7 cells by Sulforhodamine B assay, LC50 = 0.1 μM. | 21106458 | ||
A549 | Growth inhibition assay | Growth inhibition of human A549 cells by Sulforhodamine B assay, GI50 = 0.1 μM. | 21106458 | ||
A549 | Growth inhibition assay | Growth inhibition of human A549 cells by Sulforhodamine B assay, LC50 = 0.1 μM. | 21106458 | ||
RKO | Cytotoxicity assay | Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1, IC50 = 0.11 μM. | 12852768 | ||
RKO | Antiproliferative assay | Antiproliferative activity against human RKO cells by XTT assay, IC50 = 0.11 μM. | 19220018 | ||
KB/HeLa | Antiproliferative assay | Antiproliferative activity against human KB/HeLa cells by XTT assay, IC50 = 0.14 μM. | 19220018 | ||
NCI-H460 | Antiproliferative assay | Antiproliferative activity against human NCI-H460 cells by XTT assay, IC50 = 0.15 μM. | 19220018 | ||
SKOV3 | Antiproliferative assay | Antiproliferative activity against human SKOV3 cells by XTT assay, IC50 = 0.17 μM. | 19220018 | ||
HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells by SRB assay, IC50 = 0.173 μM. | 21954851 | ||
SF268 | Antiproliferative assay | Antiproliferative activity against human SF268 cells by XTT assay, IC50 = 0.3 μM. | 19220018 | ||
SK-N-SH | Growth inhibition assay | Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay, GI50 = 0.66 μM. | 21106458 | ||
HeLa | Growth inhibition assay | Growth inhibition of human HeLa cells by Sulforhodamine B assay, GI50 = 0.75 μM. | 21106458 | ||
SK-N-SH | Growth inhibition assay | Growth inhibition of human SK-N-SH cells by Sulforhodamine B assay, LC50 = 0.75 μM. | 21106458 | ||
K562 | Function assay | Inhibition of tubulin polymerization in human K562 cells, IC50 = 0.76 μM. | 20546980 | ||
HeLa | Growth inhibition assay | Growth inhibition of human HeLa cells by Sulforhodamine B assay, LC50 = 0.9 μM. | 21106458 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Nocodazole是一種微管聚合的快速可逆抑制劑,也抑制Abl、Abl(E255K)和Abl(T315I),對應的IC50值分別為0.21 μM,0.53 μM和0.64 μM。Nocodazole可提高CRISPR介導的同源重組效率,對增強精確的基因編輯效力具有加成作用。Nocodazole可誘導凋亡。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Nocodazole是癌癥相關激酶的高親和力配體,如的磷酸化ABL, c-KIT, BRAF, 和 MEK ,Kd值分別為0.091 μM, 1.6 μM, 1.8 μM 和1.6 μM,。此外,Nocodazole對ABL(E255K)磷酸化, ABL(T315I) 磷酸化, BRAF(V600E) 和 PI3Kγ 的Kd值分別是0.12 μM, 0.17 μM, 1.1 μM 和1.5 μM。Nocodazole誘導慢性淋巴細胞白血病細胞凋亡;抑制胰島素刺激的葡萄糖轉運;在人類結腸癌細胞減少細胞凋亡;損害內側神經(jīng)節(jié)嵴細胞的形態(tài)和方向遷移[1]。 Nocodazole于高濃度時,在細胞中迅速解聚微管,而低濃度可抑制微管的動態(tài)不穩(wěn)定[2]。 用Nocodazole處理經(jīng)同步化6小時的分裂期細胞,加入不同濃度的紫杉醇后,可造成G1期阻滯,半數(shù)抑制濃度為4nM。紫杉醇處理經(jīng)Nocodazole預處理的細胞,在無Nocodazole的條件下,細胞僅能形成游離微管,而在有Nocodazole存在的條件下,則可形成聚集的中心體微管[3]。 Nocodazole通過結合β-微管蛋白破壞微管,可阻礙二硫鍵形成和囊泡運輸,抑制METH誘導的細胞凋亡和溶酶體功能障礙。Nocodazole預處理可顯著減少METH誘導的細胞凋亡[4]。 在iPSC中,Nocodazole可使HDR效率加倍,可高達30%[6]。 |
|||
---|---|---|---|---|
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | Cdc2 / cyclin B1 / MAD2 / Cdc20 | 21918689 | ||
Immunofluorescence | Tubulin / LC8 Brd4 / α-tubulin | 23038268 | ||
Growth inhibition assay | Cell viability | 21918689 |
體內研究(In Vivo) | ||
體內研究活性 | Nocodazole聯(lián)合使用比單獨使用可更強地抑制小鼠的腫瘤體積和腫瘤重量。在COLO205腫瘤移植模型中聯(lián)合使用的誘導凋亡效果也比單獨使用更明顯[5]。 |
|
---|---|---|
動物實驗 | Animal Models | COLO-205腫瘤移植裸鼠 |
Dosages | 5 mg/kg | |
Administration | 腹腔注射 |
分子量 | 301.32 | 分子式 | C14H11N3O3S |
CAS號 | 31430-18-9 | SDF | Download Nocodazole SDF |
Smiles | COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 7.5 mg/mL ( (24.89 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 |
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項